Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised, Double-blind, Single-Dose, Two-way Crossover Study to Compare the PK and PD, Immunogenicity, Safety and Tolerability of Filgrastim Biosimilar and Neupogen Reference Product in Healthy Volunteers

NCT07877467 is registered in ClinicalTrials.gov with BioGeneric Pharma as lead sponsor.

NCT NCT07877467
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07877467 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised, Double-blind, Single-Dose, Two-way Crossover Study to Compare the PK and PD, Immunogenicity, Safety and Tolerability of Filgrastim Biosimilar and Neupogen Reference Product in Healthy Volunteers
Lead sponsor
BioGeneric Pharma
Phase
Phase 1
Overall status
Not yet recruiting
Start date
December 15, 2026
Completion date
May 21, 2027
Enrollment
50 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

neutropenia (low white blood cell count)